PerkinElmer Inc.
http://www.perkinelmer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PerkinElmer Inc.
Dealmaking Quarterly Statistics, Q3 2021
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions
During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.
PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M
PerkinElmer’s sales and testing capacity will expand the reach of Oxford Immunotec’s proprietary interferon gamma release tuberculosis assay technology.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Analytica of Branford, Inc.
- Arnel Inc.
- BioLegend, Inc.
- Haoyuan Biotech Co. Ltd.
- Opto Technology, Inc.
- Perten Instruments
- SYM-BIO Lifescience
- Tulip Diagnostics Private Limited
- Wallac Oy
- Vanadis Diagnostics, AB
- ViaCell
- Oxford Immunotec Global PLC